• Patient-Derived Gastric Cancer Assembloids Advance Drug Mode

  2026-05-21

  This study introduces a gastric cancer assembloid model integrating matched tumor organoids and autologous stromal cell subpopulations, significantly enhancing physiological relevance and drug response fidelity. The model provides a robust platform for dissecting tumor–stroma interactions and personalizing therapeutic strategies.

• Bradykinin (BA5201): Practical Guidance for Vascular Researc

  2026-05-21

  Bradykinin (SKU BA5201) provides a rigorously characterized endothelium-dependent vasodilator peptide for controlled studies on vascular permeability, smooth muscle contraction, and inflammation signaling. This article details practical workflows, protocol considerations, and troubleshooting steps for researchers. Bradykinin should not be used in diagnostic or clinical applications due to its research-only designation.

• TCAIM-Mediated Degradation of OGDH Regulates Mitochondrial M

  2026-05-20

  Wang et al. (2025) identify TCAIM as a mitochondrial DNAJC co-chaperone that selectively binds and facilitates the degradation of a-ketoglutarate dehydrogenase (OGDH), revealing a novel mechanism for post-translational regulation of mitochondrial metabolism. These findings highlight a previously unrecognized layer of metabolic control with implications for mitochondrial proteostasis and disease modeling.

• MLN4924 HCl Salt: Optimizing NEDD8-Activating Enzyme Inhibit

  2026-05-20

  MLN4924 HCl salt empowers researchers to dissect the neddylation pathway with precision, enabling robust investigation of protein degradation, cell cycle arrest, and viral immune evasion. This guide delivers actionable workflow enhancements and troubleshooting tips, translating landmark mechanistic insights into practical, data-driven assay design.

• ECL Chemiluminescent Substrate Detection Kit: Hypersensitive

  2026-05-19

  Unlock ultra-sensitive immunoblotting with the ECL Chemiluminescent Substrate Detection Kit (Hypersensitive), designed for reliable protein detection even at low picogram levels. Streamline your Western blot workflows and troubleshoot common detection challenges with cutting-edge HRP chemiluminescence technology.

• FGF19-ELF4 Axis Drives Colorectal Cancer Metastasis via FGFR

  2026-05-19

  This study uncovers how FGF19-induced overexpression of ELF4 accelerates colorectal cancer metastasis through transcriptional activation of FGFR4 and SRC. The findings highlight a clinically relevant positive feedback circuit and suggest new therapeutic strategies for metastatic colorectal cancer.

• Hypoxia-Driven Immunometabolism in Tumor Microenvironments

  2026-05-18

  This review elucidates how hypoxia and metabolic reprogramming drive the formation of immunosuppressive tumor microenvironments (TME). The authors systematically detail the mechanisms by which altered glucose metabolism and immune cell adaptations foster tumor progression, highlighting potential targets for metabolism-based cancer therapies.

• Sitagliptin Phosphate Monohydrate: Precision DPP-4 Inhibitor

  2026-05-18

  Harness Sitagliptin phosphate monohydrate for breakthrough metabolic disease research with robust, reproducible protocols. This article bridges innovative gastrointestinal mechanosensation studies with advanced incretin modulation assays, delivering troubleshooting guidance and actionable protocol parameters for translational investigators.

• Cyclosporin A: Molecular Precision and Assay Design in Immun

  2026-05-17

  Explore the molecular specificity of Cyclosporin A in T-cell inhibition, with a focus on cyclophilin targeting, mitochondrial regulation, and advanced assay design. Gain insights into practical protocols and recent discoveries that refine immunosuppression research.

• Revisiting Sumatriptan Metabolism: CYP and MAO Pathways Unve

  2026-05-16

  This article reviews the recent study by Pöstges and Lehr, which challenges the prevailing view that sumatriptan is metabolized solely by MAO A, demonstrating that cytochrome P450 enzymes also play a role. The findings have implications for understanding serotonergic drug metabolism and may inform future research using sodium channel blockers and 5-HT inhibitors such as Lamotrigine.

• BFH772 (VEGFR2 inhibitor): Technical Use and Protocol Guidan

  2026-05-15

  BFH772 is a highly selective VEGFR2 inhibitor designed for researchers investigating VEGFR2-mediated angiogenesis, with particular application in tumor model systems. It should not be used in protocols requiring water solubility or broad-spectrum kinase inhibition due to its defined selectivity and solubility profiles.

• Puromycin Aminonucleoside: Beyond Podocyte Models—Precision

  2026-05-15

  Explore the advanced scientific underpinnings and translational impact of puromycin aminonucleoside in nephrotoxicity research. This article uniquely dissects its mechanistic roles, assay optimization, and bridges to cutting-edge EMT research, establishing a new benchmark for utilizing this aminonucleoside moiety in renal pathology studies.

• 3X (DYKDDDDK) Peptide: Advancing Translational Protein Scien

  2026-05-14

  This thought-leadership article unpacks the mechanistic and strategic value of the 3X (DYKDDDDK) Peptide for translational researchers. Anchored in recent discoveries on protein complex regulation and tumor biology, it provides actionable guidance for maximizing reproducibility, sensitivity, and impact in recombinant protein workflows—including affinity purification, immunodetection, and structural biology. With a focus on experimental rigor and clinical translation, we highlight APExBIO’s 3X FLAG peptide as a benchmark tool, offering protocol parameters, competitive insights, and a future-focused outlook.

• Berberine & Evodiamine Target GERD via TAS2R38/TRPV1 Pathway

  2026-05-14

  This study demonstrates that berberine and evodiamine, acting through TAS2R38 and TRPV1, alleviate gastroesophageal reflux disease (GERD) by modulating MAPK/NF-κB signaling and macrophage polarization. The findings highlight a molecular mechanism that may offer new therapeutic strategies for managing GERD-associated inflammation.

• Hypoxia and Immunometabolism: Tumor Microenvironment Dynamic

  2026-05-13

  This review dissects how hypoxia-driven metabolic reprogramming and immune cell adaptation converge to create an immunosuppressive tumor microenvironment (TME). The study synthesizes mechanistic insights on glucose competition, the Warburg effect, and their implications for therapy development.

559 records 18/38 page Previous Next First page 上5页 1617181920 下5页 Last page